SCHEMBL2942616

SCHEMBL2942616

Oc1cccc(-c2cnc3ccc(NCc4ccc(F)cc4)nn23)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.76
FYN P06241 11/20 0.69
NTRK1 P04629 5/20 0.63
NTRK3 Q16288 5/20 0.63
NTRK2 Q16620 5/20 0.63
MKNK1 Q9BUB5 2/20 0.63
JAK2 O60674 1/20 0.55
ABL1 P00519 1/20 0.55
INSR P06213 1/20 0.55
LCK P06239 1/20 0.55
CSF1R P07333 1/20 0.55
LYN P07948 1/20 0.55
RET P07949 1/20 0.55
IGF1R P08069 1/20 0.55
MET P08581 1/20 0.55
ROS1 P08922 1/20 0.55
PDGFRB P09619 1/20 0.55
FGR P09769 1/20 0.55
KIT P10721 1/20 0.55
SRC P12931 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16622996 0.90 NTRK1 (0.74) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL13234281 0.88 FYN (0.71) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL13234269 0.88 FYN (0.80) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL1051257 0.86 PIM1 (1.00) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL2951889 0.85 FYN (0.63) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL4691093 0.85 FYN (0.71) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL2949572 0.85 NTRK1 (0.69) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL14605672 0.84 PIM1 (0.54) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL2945069 0.84 FYN (0.81) PIM1FYNNTRK1NTRK3NTRK2
SCHEMBL2940585 0.83 FYN (0.71) PIM1FYNNTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 PIM1 365/4885FYN 421/4885NTRK1 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.